Mumbai: A study led by Canadian researchers has proven what was feared so far by many Indian medical experts: recovery plasma therapy may be more dangerous than goodness.
Nearly 36,000 people in the state are believed to have been treated with plasma recovery through two covid waves.
Pune Division saw the highest use, followed by Nagpur and Konkan.
Concor-1 experiments published in the Nature Medicine Journal found that plasma therapy, one of the most hyped treatments, is not effective in reducing the risk of intubation (occurs in ventilators) or death.
Even worse, the recipient of blood products (33%) has significantly serious side effects, including increased oxygen needs and respiratory failure, than those who receive standard care (26.4%).
Intubation or death occurred among 32.4% of patients treated with plasma, more than 28% did not get it.
Another important learning is that variable antibody levels in patients and plasma donors affect treatment response.
“Plasma is found to have a low level of antibodies or does not function with greater risk of intubation or death,” research was found.
“Poor” antibodies in plasma can compete with antibodies that serve to thwart the immune response, researchers believe.
“It has been thought that the survivors of the blood plasma of Covid-19 will help those who are seriously ill from viruses but, unfortunately, no,” Donald Arnold, a professor at McMaster University in Canada and the study premature investigators, PTI told.
Plasma requests touch the sky during the first wave when the patient was issued to RS 60,000 for one unit.
Euphoria subsided when the Indian Medical Research Council (ICMR) revealed last year’s findings of his trial that plasma was not effective.
But it is not lost because the private sector continues its use of indiscriminately.
ICMR removes it from the treatment protocol only possible this.
Maharashtra announced its own trial, platinum project, in 150 important patients and plasma distribution for emergency use.
It was stopped in January because it turned out to be detrimental, said Dr.
Mohammed Faisal, Nodal Officer, added that the findings would be published.
According to Maharashtra FDA, 34,874 plasma units are distributed in all districts.
19,631 people have contributed 36,246 plasma bags.
Because ICMR erased it from the care protocol, they had stopped keeping notes, said an official.
The state does not have data about death caused by poor plasma events.
Dr.
Vasant Nagvekar, a member of the Covid Negara Task Force, said that with monoclonal antibodies, plasma use almost stopped.